Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation

European Journal of Radiology

Volumn 72, Issue 3, 2009, Pages 517-528

  Vogl, Thomas J ^a   Naguib, Nagy N N ^a   Zangos, Stefan ^a   Eichler, Katrin ^a   Hedayati, Alborz ^a   Nour Eldin, Nour Eldin A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

LITT; Liver; Metastases; Neuroendocrine; RF ablation; TACE

Indexed keywords

BIOLOGIC RESPONSE; CLINICAL GUIDELINE; CLINICAL PARAMETERS; EMBOLIZATION; INTERVENTIONAL; INTERVENTIONAL TREATMENT; LITT; LIVER METASTASIS; MORPHOLOGICAL RESPONSE; NEUROENDOCRINE TUMORS; RADIOFREQUENCY ABLATION; SURGICAL RESECTION; SURVIVAL RATE; TECHNICAL ASPECTS; THERMAL ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION;

ABLATION; FLUORINE CONTAINING POLYMERS; INFRARED SPECTROMETERS; ONCOLOGY; PATHOLOGY; TUMORS;

LIVER;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CYANOACRYLATE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GELFOAM; INTERFERON; IODINATED CONTRAST MEDIUM; IODINATED POPPYSEED OIL; IOPAMIDOL; LIVER ENZYME; MICROSPHERE; MITOMYCIN C; OCTREOTIDE; POLYVINYL ALCOHOL; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTIFICIAL EMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BURN; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CARCINOID SYNDROME; CHEMOEMBOLIZATION; COIL EMBOLIZATION; COLORECTAL CARCINOMA; DIARRHEA; DRUG EXCRETION; DRUG FEVER; DRUG RECEPTOR BINDING; DRUG TUMOR LEVEL; FEVER; HEMATOMA; HEPATORENAL SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; INFARCTION; INTESTINE ISCHEMIA; ISCHEMIA; LASER INTERSTITIAL THERMOTHERAPY; LEUKOCYTOSIS; LIVER ABSCESS; LIVER BLOOD VESSEL; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG CANCER; MULTIMODALITY CANCER THERAPY; NAUSEA; NEODYMIUM LASER; NEURITIS; NEUROENDOCRINE TUMOR; PAIN; PANCREAS TUMOR; PLEURA EFFUSION; PNEUMOTHORAX; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SEPSIS; SEPTICEMIA; SIDE EFFECT; STEATORRHEA; SYSTEMIC THERAPY; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT RESPONSE;

CARCINOMA, NEUROENDOCRINE; EMBOLIZATION, THERAPEUTIC; HEMOSTATICS; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS;

EID: 69249165991     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.08.008     Document Type: Review

References (63)

1. Loewe C., Schindl M., and Cejna M. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol. AJR 180 (2003) 1379-1384
2. Venook A.P. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Options Oncol 11 1 (1999) 39-44
3. Kress O., Wagner H.J., Wied M., et al. Transarterial chemoemboilzation of advanced liver metastases of neuroendocrine tumors: a retrospective single centre analysis. Digestion 68 (2003) 94-101
4. Williams E.D., and Sandler M. The classification of carcinoid tumors. Lancet 1 (1963) 238-239
5. Pelly R.J., and Bukowski R.M. Recent advances in diagnosis and therapy of neuroendocrine tumors of gasterointestinal tract. Curr Opin Oncol 9 (1997) 68-74
6. Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 25 (2001) 685-688
7. Blonski W.C., Reddy K.R., Shaked A., et al. Liver transplantation for metastatic neuroendocrine tumor: a case report and a review of literature. World J Gastroenterol 11 48 (2005) 7676-7683
8. Touzios J.G., Kiely J.M., Pitt S.C., et al. Neuroendocrine hepatic metastases: does aggressive management improve survival. Ann Surg 241 5 (2005) 776-785
9. Knox C.D., Anderson C.D., Lamps L.W., et al. Long term survival after resection of primary hepatic carcinoid tumor. Ann Surg Oncol 10 10 (2003) 1171-1175
10. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445
11. Pelage J.P., Soyer P., Boudiaf M., et al. Carcinoid tumors of the abdomen: CT features. Abdom Imaging 24 (1999) 240-245
12. McLoughlin J.M., Kuhn J.A., and Lamont J.T. Neuroendocrine tumors of the pancreas. Curr Treat Options Gastroentrol 7 (2004) 355-364
13. Kamat P.P., Gupta S., Ensor J.E., et al. Hepatic arterial embolization and chemoembolization for treatment of patients with metastatic neuroendocrine tumors. Cancer 104 8 (2005) 1590-1602
14. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38 (1996) 430-438
15. Roche A., Girish B.V., de Baère T., et al. Trans-catheter arterial chemoembolization as first line treatment for hepatic metastases from neuroendocrine tumors. Eur Radiol 13 (2003) 136-140
16. Dominguez S., Denys A., Madeira I., et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol 12 2 (2000) 141-143
17. Therasse E., Breittmayer F., Roche A., et al. Transcatheter chemoemboization of progressive carcinoid liver metastasis. Radiology 189 2 (1993) 541-547
18. Drougas J.G., Anthony L.B., Blair T.K., et al. Hepatic artery chemoembolization for the management of patients with advanced metastatic carcinoid tumors. Am J Surg 175 5 (1998) 408-412
19. Diamandidou E., Ajani J.A., Yang D.J., et al. Two phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR 170 (1998) 334-339
20. Ahlman H., Friman S., Cahlin C., et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann NY Acad Sci 1014 (2004) 265-269
21. Coppa J., Pulvirenti A., Schiavo M., et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transpl Proc 33 (2001) 1537-1539
22. Bechstein W.O., and Neuhaus P. Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann N Y Acad Sci 733 (1994) 507-514
23. Florman S., Toure B., Kim L., et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 8 (2004) 208-212
24. Sarmiento J.M., and Que F.G. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 1 (2003) 231-242
25. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12 Suppl. 2 (2001) S111-S114
26. Moertel C.G., Johnson C.M., McKusick C.A., et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120 (1994) 302-309
27. Faiss S., Pape U.F., Böhmig M., et al. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 July (14) (2003) 2689-2696
28. Oberg K., Norheim I., Lundqvist G., et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acto Oncol 26 (1987) 429-432
29. Schell S.R., Camp E.R., Caridi J.G., et al. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6 5 (2002) 664-670
30. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 8 (2005) 1590-1602
31. 90Y-DOTA-Lanreotide as effective therapy. Radiology 237 2 (2005) 718-726
32. Hellman P., Ladjevardi S., Skogseid B., et al. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26 8 (2002) 1052-1056
33. Henn A.R., Levine E.A., McNulty W., et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. Am J Roentgenol 181 4 (2003) 1005-1010
34. Elvin A., Skogseid B., and Hellman P. Radiofrequency ablation of neuroendocrine liver metastases. Abdom Imaging 30 4 (2005) 427-434
35. Gillams A., Cassoni A., Conway G., et al. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 30 (2005) 435-441
36. Vogl T.J., Mack M.G., Balzer J.O., et al. Liver metastases: neoadjuvant downsizing with transhepatic arterial chemoembolization before laser induced thermotherapy. Radiology 229 2 (2003) 457-464
37. Gillams A.R. Liver ablation therapy. Br J Radiol 77 (2004) 713-723
38. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res 22 4 (2003) 517-530
39. Feldman J.M. Carcinoid tumour and the carcinoid syndrome. Curr Probl Surg 26 (1989) 835-885
40. Soga J., Yakuwa Y., and Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 18 2 (1999) 133-141
41. Janson E.T., Holmberg L., Stridsberg M., et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral centre. Ann Oncol 8 (1997) 685-690
42. Westherg G., Wängberg B., Ahlman H., et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 88 (2001) 865-872
43. Nobin A., Mansson B., and Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol 28 3 (1989) 419-424
44. Carrasco C.H., Charnsangavej C., Ajani J., et al. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147 July (1) (1986) 149-154
45. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169 1 (1995) 36-42
46. Perry L.J., Stuart K., Stokes K.R., et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116 6 (1994) 1111-1116
47. Diaco D.S., Hajarizadeh H., Mueller C.R., et al. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 169 5 (1995) 523-528
48. Ruszniewski P., Rougier P., Roche A., et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71 8 (1993) 2624-2630
49. Stokes K.R., Stuart K., and Clouse M.E. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 4 3 (1993) 341-345
50. Desai D.C., O'Dorisio T.M., Schirmer W.J., et al. Serum Pancreastatin levels predict response to hepatic chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept 96 3 (2001) 113-117
51. Roche A., Girish B.V., de Baere T., et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51 60 (2004) 1751-1756
52. Diamandidou E., Ajani J.A., Yang D.J., et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol 170 2 (1998) 339-344
53. Ruszniewski P., and Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62 Suppl. 1 (2000) 79-83
54. Eriksson B.K., Larsson E.G., Skogseid B.M., et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 11 (1998) 2293-2301
55. Kim Y.H., Ajani J.A., Carrasco C.H., et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinomas. Cancer Invest 17 7 (1999) 474-478
56. Fiorentini G., Rossi S., Bonechi F., et al. Intra-arterial Hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemther 16 3 (2004) 293-297
57. Clouse M.E., Peerry L., Stuart K., et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 Suppl. 3 (1994) 92-97
58. Hanssen L.E., Schrumpf E., Jacobsen M.B., et al. Extended experience with recombinant alpha 2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report. Acta Oncol 30 4 (1991) 523-527
59. Skinazi F., Zins M., Menu Y., et al. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. Eur J Gastroenterol Hepatol. 8 7 (1996) 673-678
60. Brown K.T., Koh B.Y., Brody L.A., et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10 4 (1999) 1416-1417
61. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 4 (2000) 432-445
62. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 3 (2006) 401-406
63. Ho A.S., Picus J., Darcy M.D., et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 188 5 (2007) 1201-1207